{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.1","upperLimit":"47.7","value":"18.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received one 4 mg Baricitinib tablet administered orally QD.","id":"OG000","title":"4 mg Baricitinib Phase 3 Open-Label Addendum"}],"paramType":"NUMBER","populationDescription":"All randomized phase 3 open-label addendum participants who had evaluable data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 52","title":"Percentage of Participants Achieving SALT ≤ 20 - Phase 3 Open-Label Addendum","type":"SECONDARY","unitOfMeasure":"percentage of participants"}